Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
High-risk regulatory/event play: FDA has resumed review of Capricor's BLA for Deramiocel after a Class 2 resubmission (PDUFA 2026-08-22), and management has flagged an imminent HOPEâ3 top-line readout. The stock rallied ~24% over 21 days on this setup; with clear dated catalysts and recent institutional interest, trading into/around the HOPEâ3 data window offers asymmetric near-term upside (balanced by binary trial and financing risk).
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Persistent losses ⢠Rising leverage CAPR has strong near-term liquidity but remains high risk due to zero revenue, heavy losses, cash burn, and rising leverage.
Price Behavior
Key Price Behavior Insights: ⢠Strong monthly surge ⢠Near overbought ⢠Key resistance test Support Level: $9.28; stronger support at $8.29 and $6.80 Resistance Level: $10.00â$10.06 CAPR surged about 130% last month to $9.40, but near-overbought momentum and resistance at $10.00â$10.06 raise pullback risk unless it breaks higher.
Sentiment & News
Key News Insights: ⢠Fraud Litigation ⢠FDA Disclosure ⢠Investor Uncertainty Capricor faces heightened uncertainty from securities-fraud litigation, alleged FDA disclosure issues, and limited earnings-call transparency, pressuring CAPR sentiment.
AI Summary
CAPR is a high-risk regulatory-and-credibility trade: deramiocel approval could unlock major upside, but unresolved FDA/data-disclosure concerns, litigation, and heavy cash burn make waiting for definitive regulatory clarity more prudent than chasing the extended rally.
Description
Capricor Therapeutics is a clinical-stage biotechnology company developing cell- and exosome-based therapies for a range of diseases. Its lead candidate, CAP-1002, has completed a Phase III trial in late-stage Duchenne muscular dystrophy and is in Phase II testing for SARSâCoVâ2ârelated cytokine storm; the pipeline also includes a preclinical program for trauma-related injuries and vaccine candidates targeting COVIDâ19. The company outsources clinical manufacturing of CAP-1002 to Lonza Houston, was founded in 2005, and is based in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 10 | Mar 17 | CAPR | Capricor Therapeutics, Inc. | High-risk regulatory/event play: FDA has resumed review of Capricor's BLA for Deramiocel after a Class 2 resubmission (PDUFA 2026-08-22), and management has flagged an imminent HOPEâ3 top-line readout. The stock rallied ~24% over 21 days on this setup; with clear dated catalysts and recent institutional interest, trading into/around the HOPEâ3 data window offers asymmetric near-term upside (balanced by binary trial and financing risk). | Closed | -6.6% |